CORCEPT THERAPEUTICS INC Deferred Revenue
CORCEPT THERAPEUTICS INC (CORT) had Deferred Revenue of $0 as of 2016-12-31, per its 10-K filed 2017-03-06.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2017-03-06
- 2016-12-31: Deferred Revenue, Current $0.00.
- 2016-09-30: Deferred Revenue, Current $0.00.
- 2015-12-31: Deferred Revenue, Current $158.00K.
- 2015-09-30: Deferred Revenue, Current $79.00K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-06 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-02 |
| 2015-12-31 | $158.00K 10-K · filed 2017-03-06 |
| 2015-09-30 | $79.00K 10-Q · filed 2015-11-06 |
| 2015-06-30 | $37.00K 10-Q · filed 2015-08-07 |
| 2015-03-31 | $55.00K 10-Q · filed 2015-05-08 |
| 2014-12-31 | $33.00K 10-K · filed 2016-03-10 |
| 2014-09-30 | $50.00K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $44.00K 10-Q · filed 2014-08-08 |
| 2014-03-31 | $29.00K 10-Q · filed 2014-05-12 |
| 2013-12-31 | $25.00K 10-K · filed 2015-03-13 |
| 2013-09-30 | $55.00K 10-Q · filed 2013-11-12 |
| 2013-06-30 | $37.00K 10-Q · filed 2013-08-09 |
| 2013-03-31 | $76.00K 10-Q · filed 2013-05-08 |
| 2012-12-31 | $16.00K 10-K · filed 2014-03-14 |
| 2012-09-30 | $21.00K 10-Q · filed 2012-11-08 |
| 2012-06-30 | $26.00K 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |